A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of LX4211 in Patients With Inadequately Controlled Type 1 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Lexicon Pharmaceuticals; Sanofi
- 08 Sep 2015 Results will be presented at the European Association for the Study of Diabetes 2015, according to a Lexicon Pharmaceuticals media release.
- 06 Jun 2015 Results published in a Lexicon Pharmaceuticals media release.
- 06 Jun 2015 According to a Lexicon Pharmaceuticals media release, data from this trial were presented at the 75th Scientific Sessions of the American Diabetes Association (ADA) as part of 4th Annual Diabetes Care Symposium.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History